VOSE vs. MOSE in EUS-FNB for Pancreatic Masses
Comparison of Specimen Quality Using Visual On-Site Evaluation Versus Macroscopic On-Site Evaluation in Endoscopic Ultrasound-Guided Fine Needle Biopsy of Solid Pancreatic Masses: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Trial
The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200025
- Ruijin hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age above 18 years, male or female.
- Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
- Provision of signed written informed consent.
Exclusion Criteria:
- Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
- Coagulation disorders (International Normalized Ratio [INR] ≥ 1.5, platelet count ≤ 50 × 10^9/L) or current use of anticoagulant or antiplatelet medications.
- Confirmed or suspected pregnancy.
- Pathological diagnosis has already been established by other methods.
- Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
- Any other conditions that preclude the performance of EUS-FNB.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: VOSE Group (Visual On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and visible tissue cores are placed into formalin for visual grading. If no "red mixed specimen" is observed, additional passes are performed up to 3 passes. The number of passes and puncture time are recorded. |
VOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide. Visible tissue cores are placed into a formalin vial, gently shaken to dissolve blood, and visually graded with photographic recording. If the first-pass specimen is not a "red mixed specimen," additional passes are performed until a "red mixed specimen" appears or a maximum of 3 passes is reached. |
|
Aktiv komparator: MOSE Group (Macroscopic On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and the macroscopic visible core (MVC) length is measured. If the MVC is < 10mm, additional passes are performed until the total MVC is ≥ 10mm or up to 3 passes. The number of passes and puncture time are recorded. |
MOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide, and the length of the macroscopic visible core (MVC) is measured. If the total MVC length is less than 10 mm, additional passes are performed until the total MVC is ≥ 10 mm or a maximum of 3 passes is reached. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Histopathological diagnostic accuracy
Tidsramme: Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of histopathological tissue obtained by EUS-FNB in the VOSE group compared to the MOSE group, using the final surgical pathology or clinical/radiological follow-up as the gold standard. |
Within 30 days after the EUS-FNB procedure
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic sensitivity
Tidsramme: Within 30 days after the EUS-FNB procedure
|
The diagnostic sensitivity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Diagnostic specificity
Tidsramme: Within 30 days after the EUS-FNB procedure
|
The diagnostic specificity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Median number of needle passes
Tidsramme: During the EUS-FNB procedure
|
The number of needle passes required to obtain adequate tissue samples (until a "red mixed specimen" or MVC ≥ 10mm is observed, up to 3 passes). |
During the EUS-FNB procedure
|
|
Puncture time
Tidsramme: During the EUS-FNB procedure
|
The duration of the puncture procedure (from the start of the first needle pass to the end of sampling). |
During the EUS-FNB procedure
|
|
Cytological diagnostic accuracy
Tidsramme: Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of liquid-based cytology obtained from residual specimens in VOSE and MOSE groups, compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- RJ2026164
- 82570763 (Annet stipend/finansieringsnummer: National Nature Science Foundation of China)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .